Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight 40 to 136 kg (88 to 300 lbs)~* Recent history of GERD related symptoms (at least twice weekly) confirmed during screening.~* Recent history of 8 week PPI treatment without significant improvement~* Abnormal bilirubin level as assessed by Bilitec~* Normal esophageal pH value (pH\<4.0 for \<4.2% of the time calculated over a 24 hour period)~* Platelet count (thrombocytes) \>100,000/µL~* Normal Hgb and Hct levels~* Able and willing to comply with all protocol procedures for the planned duration of the study~* Able and willing to understand, sign and date an informed consent document, and authorize access to protected health information.~* Females must be postmenopausal, surgically incapable of bearing children, or practicing a reliable method of birth control (hormonal contraceptives, intrauterine devices, spermicide and barrier). Partner/spouse sterility may also qualify at the Investigator's discretion. Females of child-bearing potential must have a negative urine pregnancy test at baseline.~Exclusion Criteria:~* Concurrent GI or other pathology which could interfere with the course of the study (e.g., erosive esophagitis, malabsorption, cirrhosis, ascites, bleeding ulcer, diabetes, scleroderma, non-GI myopathy or neuropathy etc.) Note: patients with Barrett's esophagus (short segment defined as \< 3 cm) can be included.~* Patients with cancer or undergoing chemotherapy for the treatment of cancer~* Patients with a history of upper GI surgery~* Patients with GERD complications such as stricture of the esophagus~* Contraindication to continued PPI treatment~* Patients requiring the concomitant use of NSAIDs for the duration of the study~* Uncontrolled systemic disease~* Diagnosis of a psychiatric disorder within the past 2 years and not on a stable dose of medications for at least 6 months~* Other major physical or psychiatric illness in previous 6 months as determined by the treating physician~* Known hypersensitivity or contraindication to any component of the test product (study drug) or diagnostics used~* Participation in another study within eight (8) weeks prior to randomization~* Unable to attend all visits required by the protocol~* Pregnant, breast feeding, or planning to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AST-120, 2 gram sachets
- 2 (Type: PLACEBO_COMPARATOR): Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.

Based on this trial design, predict the completion outcome and termination type (if applicable).